Odyssey Marine Exploration Reports First Quarter 2017 Results
May 11, 2017 11:01 am UTC| Business
TAMPA, Fla., May 11, 2017 -- Odyssey Marine Exploration, Inc. (NASDAQ:OMEX), a pioneer in the field of deep-ocean exploration, reported results for the first quarter ended March 31, 2017. Q1 2017 Highlights Mobilized...
Odyssey Marine Exploration Reports First Quarter 2017 Results
May 11, 2017 11:01 am UTC| Business
TAMPA, Fla., May 11, 2017 -- Odyssey Marine Exploration, Inc. (NASDAQ:OMEX), a pioneer in the field of deep-ocean exploration, reported results for the first quarter ended March 31, 2017. Q1 2017 Highlights Mobilized...
May 11, 2017 11:01 am UTC| Business
Results support AGTC’s clinical development strategies in both conditions Phase 1/2 trial in patients with achromatopsia due to CNGB3 mutations is currently enrolling patients; Phase 1/2 trial in patients with...
May 11, 2017 11:01 am UTC| Business
Results support AGTC’s clinical development strategies in both conditions Phase 1/2 trial in patients with achromatopsia due to CNGB3 mutations is currently enrolling patients; Phase 1/2 trial in patients with...
Recro Pharma Reports First Quarter 2017 Financial Results
May 11, 2017 11:00 am UTC| Business
Reports First Quarter 2017 Revenues of $18.7 Million Recently Announced Successful Top-Line Results from Phase III Safety Study of IV Meloxicam On Track to File NDA with U.S. FDA for IV Meloxicam During Early Q3 2017 ...
Reata pharmaceuticals, inc. announces first quarter 2017 financial and operating results
May 11, 2017 11:00 am UTC| Business
IRVING, Texas, May 11, 2017 -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2017,...
Bio-Path Holdings Reports First Quarter 2017 Financial Results
May 11, 2017 11:00 am UTC| Business
HOUSTON, May 11, 2017 -- Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid...